Solute Carrier Family 29 Member (ENT) and Its Potential Therapeutic Applications

Target Name: Solute carrier family 29 member

NCBI ID: P11340

Solute carrier family 29 member

Other Name(s): ENT

Solute Carrier Family 29 Member (ENT) and Its Potential Therapeutic Applications

Solute carrier family 29 member (nonspecified subtype) (ENT) is a protein that is expressed in various tissues throughout the body. It plays a crucial role in the transport of solutes, including ions, nutrients, and medications across cell membranes. ENTs are also involved in the regulation of cell signaling pathways and are potential drug targets.

The solute carrier family 29 member (nonspecified subtype) (ENT) is a transmembrane protein that is expressed in various tissues throughout the body. It is made up of four subunits, which are composed of a catalytic heads and a transmembrane region. The catalytic heads contain the enzymes that handle the solute transport, while the transmembrane region is responsible for the stability and regulation of the ENT.

ENTs are involved in the transport of a wide range of solutes, including ions, nutrients, and medications across cell membranes. For example, ENTs are responsible for the transport of glucose, insulin, and other carbohydrates across the endocellular membrane of pancreatic beta-cells . They also play a role in the transport of amino acids, such as glutamine, across the cytoplasmic membrane of cancer cells. In addition to their role in solute transport, ENTs are also involved in the regulation of cell signaling pathways.

The ENTs are involved in many different signaling pathways, including cell division, cell growth, and cell survival. For example, ENTs are involved in the regulation of the cyclic AMP signaling pathway, which is involved in cell signaling and proliferation. They are also involved in the regulation of the NF-kappa-B signaling pathway, which is involved in inflammation and stress responses.

ENTs have also been identified as potential drug targets. The ability of ENTs to regulate cell signaling pathways makes them an attractive target for small molecules and other therapeutic agents. In addition, ENTs are also involved in the regulation of cell shape and movement, which makes them an attractive target for agents that want to alter the structure and function of cancer cells.

The ENTs are also involved in the regulation of cell adhesion and migration. The ENTs are responsible for the transmembrane delivery of adhesion molecules, such as cadherins and integrins, which are involved in cell adhesion and migration. This is important for the development and maintenance of tissues and organs, including the brain and nervous system.

In conclusion, the solute carrier family 29 member (nonspecific subtype) (ENT) is a transmembrane protein that is involved in the transport of solutes across cell membranes and in the regulation of cell signaling pathways. ENTs are potential drug targets due to their involvement in cell signaling pathways and their role in the regulation of cell shape, adhesion, and migration. Further research is needed to fully understand the function and potential therapeutic applications of ENTs.

Protein Name: Solute Carrier Family 29 Member (nonspecified Subtype)

The "Solute carrier family 29 member Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Solute carrier family 29 member comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets